New Releases from NCBI BookshelfElafibranor (Iqirvo): Indication: For the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA: Reimbursement Recommendation [Internet].​Elafibranor (Iqirvo): Indication: For the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA: Reimbursement Recommendation [Internet].

By /

Canada’s Drug Agency (CDA-AMC) recommends that Iqirvo be reimbursed by public drug plans for the treatment of primary biliary cholangitis (PBC) in adults with an inadequate response to ursodeoxycholic acid (UDCA), or as monotherapy in adults who are unable to tolerate UDCA, if certain conditions are met.

​ 

Leave a Comment

Your email address will not be published. Required fields are marked *

Useful Links

NEWREDMARS SKILL AND RESEARCH        FOUNDATION

Registration No: 771800548      Contact Number : +91-8249516996

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.

Scroll to Top